120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
阿布昔替尼成功治疗大疱性类天疱疮合并寻常型银屑病：病例报告和文献综述
Authors Hu YQ , Zhang JZ, Zhao Y
Received 15 September 2025
Accepted for publication 12 December 2025
Published 27 January 2026 Volume 2026:19 566664
DOI https://doi.org/10.2147/CCID.S566664
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Michela Starace
Yu-Qing Hu, Jian-Zhong Zhang, Yan Zhao
Department of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China
Correspondence: Yan Zhao, Department of Dermatology, Peking University People’s Hospital, No. 11 South Avenue, Xi Zhi Men Street, Xicheng District, Beijing, People’s Republic of China, Email zhaoyan377@hotmail.com
Abstract: Bullous pemphigoid (BP) and psoriasis are common immune-related dermatosis. The concurrence of these two diseases is rare. The coexistence of the two conditions imposes a difficult therapeutic challenge. We reported a case of concurrence of BP and psoriasis vulgaris which was successfully treated by abrocitinib. Based on our research, abrocitinib appears to be an effective and safe therapeutic option for patients with concurrent BP and psoriasis.
Keywords: bullous pemphigoid, psoriasis, Janus kinase inhibitors, abrocitinib
Department of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China
Correspondence: Yan Zhao, Department of Dermatology, Peking University People’s Hospital, No. 11 South Avenue, Xi Zhi Men Street, Xicheng District, Beijing, People’s Republic of China, Email zhaoyan377@hotmail.com
Abstract: Bullous pemphigoid (BP) and psoriasis are common immune-related dermatosis. The concurrence of these two diseases is rare. The coexistence of the two conditions imposes a difficult therapeutic challenge. We reported a case of concurrence of BP and psoriasis vulgaris which was successfully treated by abrocitinib. Based on our research, abrocitinib appears to be an effective and safe therapeutic option for patients with concurrent BP and psoriasis.
Keywords: bullous pemphigoid, psoriasis, Janus kinase inhibitors, abrocitinib